SOST and chronic kidney disease: In reported mice models, an early increase in sclerostin-positive osteocytes correlated with an increased expression of inactive phosphorylated β-catenin, which suggests an overall repression in Wnt/β-catenin signaling that may contribute to the progression of chronic kidney disease–mineral bone disorder (a.k.a. CKD–MBD) [84,85].